ArticleTherapeutic advances in medical oncology2020

A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.

Valeria Merz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.